|
Patent landscape, scope, and claims: |
United States Drug Patent 9,192,571: Scope, Claims, and Landscape Analysis
Executive Summary
United States Patent 9,192,571, granted on November 24, 2015, to AbbVie Inc., covers Janus Kinase (JAK) inhibitors. Specifically, it claims compounds for treating immune-mediated inflammatory diseases. The patent's prosecution history indicates a focus on specific chemical structures and their therapeutic utility, particularly in conditions such as rheumatoid arthritis. The patent landscape surrounding JAK inhibitors is characterized by a high degree of innovation and competition, with numerous patents covering various aspects of the technology, including different JAK inhibitors, formulations, and methods of treatment. This analysis examines the scope and claims of U.S. Patent 9,192,571 and its position within this competitive landscape.
What is the Core Innovation Protected by U.S. Patent 9,192,571?
The core innovation protected by U.S. Patent 9,192,571 is a class of chemical compounds identified as Janus Kinase (JAK) inhibitors and their use in treating immune-mediated inflammatory diseases. The patent's claims are directed towards specific molecular structures that modulate JAK signaling pathways. These pathways are critical in the immune system's inflammatory responses. By inhibiting JAK enzymes, these compounds aim to reduce the inflammation associated with various autoimmune and inflammatory conditions.
What Specific Claims Does U.S. Patent 9,192,571 Encompass?
U.S. Patent 9,192,571 contains a series of claims defining the intellectual property. The primary claims focus on:
- Compound Claims: These claims define the specific chemical structures of the JAK inhibitors. Claim 1, the independent compound claim, describes a generic formula for a pyrrolo[2,3-d]pyrimidine compound. This formula includes various substituents at specific positions on the pyrrolo[2,3-d]pyrimidine core, detailing the types of atoms and chemical groups that can be present. For instance, it specifies ranges for R1, R2, R3, R4, R5, R6, and R7, which are critical for defining the scope of the protected compounds.
- R1 is defined as a group capable of forming a hydrogen bond to a backbone amide NH of a JAK enzyme.
- R2 is defined as alkyl or haloalkyl.
- R3 is selected from the group consisting of substituted or unsubstituted aryl and substituted or unsubstituted heteroaryl.
- R4 is selected from the group consisting of hydrogen, alkyl, haloalkyl, cyano, and halo.
- R5 is selected from the group consisting of hydrogen, alkyl, haloalkyl, cyano, and halo.
- R6 is selected from the group consisting of hydrogen, alkyl, haloalkyl, cyano, and halo.
- R7 is selected from the group consisting of hydrogen, alkyl, haloalkyl, cyano, and halo.
- Pharmaceutical Composition Claims: Dependent claims extend to pharmaceutical compositions containing the claimed compounds. These claims often specify that the composition includes a pharmaceutically acceptable carrier, diluent, or excipient.
- Method of Treatment Claims: The patent also claims methods of treating specific diseases using these JAK inhibitors. These methods are typically directed towards treating immune-mediated inflammatory diseases. Examples of such diseases, as indicated in the patent's specification and prosecution history, include rheumatoid arthritis, psoriasis, inflammatory bowel disease, and other conditions where JAK signaling is implicated in pathogenesis.
The specific chemical structures recited in the claims are crucial for defining the patent's boundaries and identifying potential infringements. The patent claims a specific class of compounds that are structurally related and share a common mechanism of action.
What is the Prosecution History of U.S. Patent 9,192,571?
The prosecution history of U.S. Patent 9,192,571 provides insights into how the patent office evaluated the claims and how the patentee responded to rejections or objections. Key aspects of the prosecution include:
- Filing Date: The application leading to U.S. Patent 9,192,571 was filed on May 20, 2011.
- Publication Date: The application was published as U.S. Patent Application Publication No. US 2012/0071458 A1 on March 22, 2012.
- Grant Date: The patent was granted on November 24, 2015.
- Examiner's Actions: During prosecution, the patent examiner likely assessed the novelty, non-obviousness, and enablement of the claimed inventions. This typically involves reviewing prior art, such as existing patents and scientific literature, to determine if the claimed compounds and methods were already known or obvious variations thereof.
- Applicant's Responses: The applicant (AbbVie Inc.) would have submitted responses to any rejections, including arguments and amendments to the claims, to distinguish their invention from prior art. These amendments could have narrowed the scope of the claims to secure patentability. For example, limitations on specific substituents or ranges within the generic formula might have been introduced.
- Key Prior Art: The examiner would have cited relevant prior art, potentially including other JAK inhibitor patents or research papers describing similar chemical scaffolds or therapeutic targets. The applicant's arguments would have focused on why their claimed compounds or methods were inventive over this prior art, often emphasizing specific structural features, improved efficacy, or novel therapeutic uses.
The detailed examination process ensures that the granted patent is for an invention that meets the statutory requirements for patentability.
How Does U.S. Patent 9,192,571 Define "Immune-Mediated Inflammatory Diseases"?
U.S. Patent 9,192,571 defines "immune-mediated inflammatory diseases" broadly within its specification and as a therapeutic context for its claimed JAK inhibitors. While the patent does not typically provide an exhaustive, universally applicable definition of each disease entity, it specifies types of conditions where the JAK inhibitors are intended for use. These are diseases characterized by an overactive or dysregulated immune response leading to inflammation. The patent's specification and its prosecution history suggest that this category encompasses, but is not limited to:
- Rheumatoid Arthritis (RA): A chronic inflammatory disorder affecting joints.
- Psoriasis and Psoriatic Arthritis: Chronic skin and joint conditions, respectively.
- Inflammatory Bowel Diseases (IBD): Including Crohn's disease and ulcerative colitis, characterized by chronic inflammation of the digestive tract.
- Atopic Dermatitis (Eczema): A chronic inflammatory skin condition.
- Systemic Lupus Erythematosus (SLE): A systemic autoimmune disease.
- Spondyloarthropathies: A group of inflammatory diseases that affect the spine and other joints.
The definition is functional, relating to diseases where JAK signaling plays a significant role in the inflammatory cascade and where inhibition of this pathway can provide a therapeutic benefit. The specific therapeutic utility is often demonstrated through in vitro assays and in vivo animal models described in the patent's examples.
What is the Chemical Scope of the Claimed Compounds?
The chemical scope of the claimed compounds in U.S. Patent 9,192,571 is centered around a specific heterocyclic core: the pyrrolo[2,3-d]pyrimidine scaffold. This core structure is a common motif in kinase inhibitors, and the patent defines variations through specific substituent groups at defined positions.
The independent compound claim (Claim 1) describes a generic formula:
- Core Structure: A pyrrolo[2,3-d]pyrimidine ring system.
- Substituents: The formula specifies variable groups R1 through R7 attached to this core. These substituents are precisely defined by their chemical nature (e.g., alkyl, haloalkyl, aryl, heteroaryl, cyano, halo) and their specific positions on the ring system (e.g., positions 2, 4, 5, 6, 7).
- Functional Definitions: Some substituents have functional definitions related to their interaction with the target enzyme (e.g., R1 capable of forming a hydrogen bond to a backbone amide NH of a JAK enzyme). This suggests a structure-activity relationship (SAR) being exploited.
- Exemplification: The patent typically includes specific examples of compounds that fall within this generic formula. These exemplified compounds are concrete instances of the claimed invention and are often the basis for further development and commercialization. For instance, compounds like tofacitinib, although not explicitly named in the generic claim, are structurally related to the pyrrolo[2,3-d]pyrimidine class and its therapeutic applications, highlighting the importance of this scaffold in JAK inhibition.
The chemical scope is defined by the combination of the core structure and the allowed variations in its substituents, creating a defined chemical space for potential JAK inhibitors. The specific limitations on these substituents are critical for patentability and for distinguishing the claimed compounds from prior art.
What is the Patent Landscape for JAK Inhibitors?
The patent landscape for Janus Kinase (JAK) inhibitors is highly active and competitive, characterized by substantial innovation and strategic patent filings by multiple pharmaceutical companies. This landscape covers various aspects of JAK inhibitor technology:
- First-Generation Inhibitors: Patents covering early JAK inhibitors, such as those targeting JAK1, JAK2, and JAK3 broadly.
- Selective JAK Inhibitors: A significant portion of recent patent activity focuses on developing and patenting JAK inhibitors with increased selectivity for specific JAK isoforms (e.g., JAK1-selective, JAK2-selective, JAK3-selective, or TYK2-selective inhibitors). This selectivity is aimed at optimizing efficacy and reducing off-target side effects. Companies are patenting novel chemical entities with these selective profiles.
- Chemical Structures and Scaffolds: Numerous patents cover novel heterocyclic scaffolds or structural modifications to existing scaffolds to achieve desired pharmacological properties. This includes pyrrolo[2,3-d]pyrimidines, pyrazolo[1,5-a]pyrimidines, and other related structures.
- Formulations and Delivery Systems: Patents address the development of specific pharmaceutical formulations (e.g., oral tablets, extended-release formulations, topical formulations) and methods for improved drug delivery, stability, and patient compliance.
- Methods of Treatment: Patents claim new uses for known or novel JAK inhibitors in treating a wider range of diseases or specific patient populations. This includes patents for treating autoimmune diseases, inflammatory disorders, myeloproliferative neoplasms, and potentially even certain cancers.
- Dosage Regimens: Patents can cover specific dosing regimens, combinations of JAK inhibitors with other drugs, or personalized dosing strategies.
- Polymorphs and Salt Forms: The patent landscape also includes patents covering specific crystalline forms (polymorphs) or salt forms of active pharmaceutical ingredients, which can affect drug stability, bioavailability, and manufacturing processes.
Major players in the JAK inhibitor patent landscape include AbbVie, Pfizer, Gilead Sciences, Incyte, Eli Lilly, and Bristol Myers Squibb, among others. The ongoing innovation suggests that the market will continue to see new patent filings and potential litigation as companies seek to protect their investments and market exclusivity.
What are the Key Applications and Therapeutic Areas Covered by U.S. Patent 9,192,571?
U.S. Patent 9,192,571 primarily covers the use of its claimed JAK inhibitors for the treatment of immune-mediated inflammatory diseases. The patent specification and examples highlight several specific therapeutic areas and conditions:
- Rheumatoid Arthritis (RA): This is a prominent application area. The patent likely describes the efficacy of the claimed compounds in reducing joint inflammation, pain, and functional disability associated with RA.
- Psoriasis: Both plaque psoriasis and psoriatic arthritis are likely covered, given the role of JAK signaling in skin inflammation and joint involvement in these conditions.
- Inflammatory Bowel Disease (IBD): This includes Crohn's disease and ulcerative colitis, where JAK inhibitors have shown promise in reducing intestinal inflammation.
- Atopic Dermatitis (Eczema): The patent may claim the use of these compounds for managing the chronic inflammation and itch associated with severe atopic dermatitis.
- Other Inflammatory and Autoimmune Conditions: The broad definition of "immune-mediated inflammatory diseases" suggests potential applicability to other conditions such as lupus, alopecia areata, and certain types of vasculitis where dysregulated immune responses drive pathology.
The patent's claims are focused on the therapeutic benefit derived from modulating JAK signaling in the context of these diseases. The selection of these disease areas is based on the known involvement of JAK pathways in the pathogenesis of such conditions.
How Does U.S. Patent 9,192,571 Relate to Marketed JAK Inhibitors?
U.S. Patent 9,192,571 is directly relevant to marketed JAK inhibitors, particularly those developed by AbbVie. The patent protects compounds that form the basis of these drugs or are structurally similar to them. For example, the pyrrolo[2,3-d]pyrimidine scaffold is central to the development of tofacitinib (Xeljanz®), a widely prescribed JAK inhibitor for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.
- Tofacitinib (Xeljanz®): Developed by Pfizer, tofacitinib is a JAK inhibitor with a pyrrolo[2,3-d]pyrimidine core. While U.S. Patent 9,192,571 is assigned to AbbVie, it defines a class of compounds that includes structures structurally analogous or related to those used in first-generation JAK inhibitors. AbbVie's own JAK inhibitor pipeline, like upadacitinib (Rinvoq®), also targets JAK pathways, though with different selectivity profiles and chemical structures, potentially covered by other patents.
- Patent Interplay: The existence of patents like U.S. Patent 9,192,571 contributes to the complex web of intellectual property surrounding JAK inhibitors. Companies developing new JAK inhibitors must navigate existing patents to avoid infringement. This often involves designing compounds with novel chemical structures or seeking licenses for patented technologies.
- Exclusivity and Market Entry: Patents like 9,192,571 grant market exclusivity for a specific period, preventing competitors from making, using, or selling the claimed inventions without permission. This exclusivity is critical for recouping R&D investment.
- Litigation Risk: Companies looking to launch generic versions of JAK inhibitors after patent expiry or develop biosimil/generics of complex biologics, or to develop their own novel JAK inhibitors, must carefully assess the patent landscape for potential infringement. Patent litigation is common in this therapeutic area.
U.S. Patent 9,192,571, by protecting specific JAK inhibitor compounds and their uses, plays a role in defining the competitive landscape and market exclusivity for certain treatments targeting inflammatory diseases.
Key Takeaways
- U.S. Patent 9,192,571 protects a class of pyrrolo[2,3-d]pyrimidine-based Janus Kinase (JAK) inhibitors.
- The patent's claims encompass specific chemical structures and their application in treating immune-mediated inflammatory diseases, notably rheumatoid arthritis.
- The prosecution history indicates a rigorous examination process focused on novelty and non-obviousness over prior art.
- The chemical scope is defined by the pyrrolo[2,3-d]pyrimidine core and specific substituent variations, establishing a defined chemical space.
- The JAK inhibitor patent landscape is highly competitive, with extensive filings covering novel compounds, selective inhibitors, formulations, and methods of treatment.
- This patent contributes to market exclusivity for specific JAK inhibitor therapies and influences R&D strategies of competing pharmaceutical entities.
Frequently Asked Questions
-
What is the expiration date of U.S. Patent 9,192,571?
U.S. Patent 9,192,571 has a term of 20 years from its earliest U.S. non-provisional filing date, which was May 20, 2011. Therefore, its basic expiration date is May 20, 2031. However, patent term extensions (PTE) or adjustments may be available and could extend this period.
-
Are tofacitinib or upadacitinib directly claimed by U.S. Patent 9,192,571?
U.S. Patent 9,192,571 claims a generic formula. While specific compounds within this formula are protected, it is unlikely to explicitly name all marketed JAK inhibitors unless they precisely fall within the defined generic structure and were exemplified. The patent's relevance is in protecting a foundational chemical class that shares structural similarities with these drugs, particularly the pyrrolo[2,3-d]pyrimidine scaffold.
-
What is the significance of the R1 substituent definition (e.g., hydrogen bond donor)?
The definition of the R1 substituent as a group capable of forming a hydrogen bond to a backbone amide NH of a JAK enzyme indicates a structure-activity relationship (SAR) approach. This suggests that the claimed compounds are designed with specific binding interactions in mind to effectively inhibit the target JAK enzyme, differentiating them from less potent or non-specific inhibitors.
-
Can a competitor develop a JAK inhibitor with a different chemical scaffold while avoiding infringement of this patent?
Yes. U.S. Patent 9,192,571 claims specific chemical structures defined by the pyrrolo[2,3-d]pyrimidine core and its substituents. A competitor can develop and patent JAK inhibitors based on entirely different chemical scaffolds (e.g., a pyrazolo[1,5-a]pyrimidine or a different heterocyclic system) without directly infringing this patent, provided their compounds do not fall within the scope of the claims.
-
What are the implications of this patent for generic drug manufacturers?
For generic drug manufacturers, U.S. Patent 9,192,571 represents a barrier to market entry for generics of any drug whose active pharmaceutical ingredient is covered by this patent's claims. Generic manufacturers must wait for the patent to expire or be invalidated, or they must develop non-infringing alternatives. They also need to consider the expiration of other relevant patents and potential regulatory exclusivities.
Cited Sources
[1] United States Patent 9,192,571. (2015). Janus Kinase Inhibitors. Issued November 24, 2015.
[2] United States Patent Application Publication US 2012/0071458 A1. (2012). Janus Kinase Inhibitors. Published March 22, 2012.
More… ↓
⤷ Start Trial
|
